Skip to main content
logo
Brainstorm Cell Therapeutics Inc. (BCLI)
OTCMKTS · Delayed Price · Currency is USD
1.060
-0.157 (-12.94%)
At close: Aug 20, 2026

BCLI Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-10.31-11.62-17.19-24.28-24.46
Depreciation & Amortization
0.20.240.270.290.26
Stock-Based Compensation
1.520.751.491.681.37
Change in Accounts Receivable
---0.481.070.34
Change in Accounts Payable
0.991.13-1.272.52-1.72
Change in Other Net Operating Assets
0.630.41-3.28-0.6-2.05
Operating Cash Flow
-6.98-9.09-20.46-19.32-26.27
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
---0.02-0.03-0.33
Sale of Property, Plant & Equipment
-0.01---
Investment in Securities
--2.211.030.65
Investing Cash Flow
-0.012.1910.32

Financing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
0.58----
Total Debt Issued
0.58----
Net Debt Issued (Repaid)
0.58----
Issuance of Common Stock
4.357.9718.980.246.97
Other Financing Activities
1.95----
Financing Cash Flow
6.887.9718.980.246.97

Net Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-0.1-1.110.71-18.08-18.97

Free Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-6.98-9.09-20.48-19.35-26.6
Free Cash Flow Growth
-----
Free Cash Flow Per Share
-0.75-1.81-7.13-7.95-11.03
Levered Free Cash Flow
-3.21-5.03-12.49-10-17.64
Unlevered Free Cash Flow
-2.88-4.99-12.31-10-17.64

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
1.611.54-5.022.99-3.43